Abstract
Methods Uncontrolled personal observations of dubious references in the headache literature. Examples: Statement: Nagata et al. (4) reported that spontaneous migraine was not associated with any dilation of the middle meningeal artery as measured by MRA. Reference: 4. Nagata E, et al. The middle meningeal artery during a migraine attack: 3T magnetic resonance angiography study. Intern Med 2009; 48: 2133–2135. Comment: Note that only one migraine attack was studied. Statement (from a kinetic study on orally inhaled DHE): Other routes of administration such as nasal delivery (40% bioavailability) have erratic and somewhat unpredictable pharmacokinetic (PK) properties that pose therapeutic challenges (eg, unpredictable clinical response or adverse events)(4) Reference: 4. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46 (Suppl 4): S171-81(in this reference no mention at all of inconsistent kinetics of nasal DHE). Comment: The statement is from an industry-sponsored paper on kinetics of the new orally inhaled DHE and discredits to some extent nasal DHE. However, an extensive study of nasal DHE from 1996 demonstrated “the reliability and reproducibility” of nasal DHE’s pharmacokinetics (Humbert H, et al. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther 1996; 60: 265–275).
Highlights
The problem with references is incorrect use to support statements in the text
Examples: Statement: Nagata et al (4) reported that spontaneous migraine was not associated with any dilation of the middle meningeal artery as measured by MRA
Statement: Other routes of administration such as nasal delivery (40% bioavailability) have erratic and somewhat unpredictable pharmacokinetic (PK) properties that pose therapeutic challenges(4)
Summary
From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark. 18-21 September 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
